Skip to main content
. 2022 Jan 12;46(3):581–588. doi: 10.1007/s00264-022-05300-9

Table 3.

Changes in the mean PRTEE and qDASH scales during the follow-up period

Variable Mean PRTEE score P value Mean qDASH P value
Treatment group (mean ± SD) Control group (mean ± SD) Treatment group (mean ± SD) Control group (mean ± SD)
Pre-injection 90 ± 7.49 93 ± 7.23 0.85 78.6 ± 6.8 77.7 ± 8.94 0.79
At 1-month 33.7 ± 6.5 89.1 ± 12.3  < 0.001 42.8 ± 8.9 78.2 ± 11.3  < 0.001
At 3-month 10.2 ± 2.4 73.2 ± 9.9  < 0.001 23.1 ± 8.6 66.1 ± 12.1  < 0.001
At 6-month 9.5 ± 1.6 75.4 ± 6.9  < 0.001 24 ± 5.6 60.2 ± 7.9  < 0.001
At 12-month 10.8 ± 2.0 69.6 ± 7.2  < 0.001 24.5 ± 6.0 54.1 ± 9.4  < 0.001
P Repeated measures ANOVA ˂0.001 ˂0.001
Paired difference* (mean ± SD) 80.3 ± 8.7 20.5 ± 3.9  < 0.001 55.5 ± 6.3 11.6 ± 1.8  < 0.001
Percentage of score reduction** (mean ± SD) 88.7 ± 9.5 21.8 ± 4.4  < 0.001 70.6 ± 8.1 14.9 ± 2.6  < 0.001

PRTEE, Patient-Related Tennis Elbow Evaluation; qDASH, quick Disabilities of the Arm, Shoulder and Hand. *Difference between values for each case at 3-month follow-up and pre-injection was calculated for both scores in both groups. A new variable (paired difference) for which the mean and SD were calculated; **paired difference/score pre-injection. Pairwise comparisons were done by multiple paired t tests with a Bonferroni correction to keep the type I error at 5% overall